India Pharma - Yet Another Quarter Of Double-Digit Growth For The IPM: Anand Rathi

India Pharma - Yet Another Quarter Of Double-Digit Growth For The IPM: Anand Rathi

<div class="paragraphs"><p>A pharmacy. (Source: freepik)</p></div>
A pharmacy. (Source: freepik)

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Anand Rathi Report

Once again, in July 2022 the Indian pharma market grew in double digits, 14.1% YoY, driven by volumes (6.4% YoY), price hikes (6.3%) and new products (1.5%).

On a moving annual total basis, it grew 6.7% YoY largely from price hikes (5.5%) and new products (1.1%), while volumes were flat.

Strong traction was seen in most key therapies: derma was up 22.3% YoY, respiratory 16.9%, pain 16.7% and gastrointestinal neuro/central nervous system and cardiac therapies 14-15%.

Sub-chronic therapies grew the most (15.8% YoY); chronic and acute therapies grew respectively 14% and 13.4% YoY.

Click on the attachment to read the full report:



This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.